AIDS test adulteration
This article was originally published in The Gray Sheet
Executive Summary
Bioelectrical impedance analysis (BIA) device manufacturer RJL Sciences and President Rudolph Liedtke plead guilty April 19 in Boston federal court. They admit to disseminating adulterated computer software products to promote diagnoses of AIDS wasting and boost sales of an AIDS-wasting drug, according to a release issued by U.S. attorney Michael Sullivan. The software packages, for use in combination with a BIA device to estimate body composition, were not FDA-approved. With sentencing scheduled for Sept. 13, Liedtke faces up to five years' imprisonment and a $250,000 fine, while RJL could be fined up to $500,000. FDA is taking part in the ongoing investigation...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.